German Watchdog Imposes an Almost $14 Million Fine on Citigroup Subsidiary
By Matthias Goldschmidt
Germany's financial watchdog imposed a 12.975 million euros ($13.9 million) fine on Citigroup Global Markets Europe for violating securities trading regulations.
The federal financial supervisory authority, known as Bafin, said Thursday that in May 2022, the bank didn't have the proper systems and risk controls in place to ensure appropriate trading thresholds and limits. There was also no guarantee that incorrect orders wouldn't be transmitted, as the trading system didn't recognize a manual input error by a trader and transmitted incorrect orders, causing a market disruption, Bafin said.
"We are pleased to resolve this matter from more than two years ago, which arose from an individual error that was identified and corrected within minutes. We immediately took steps to strengthen our systems and controls, and remain committed to ensuring full regulatory compliance," the company said.
Citigroup Global Markets Europe has outsourced its monitoring and administration system for algorithmic trading to Citigroup Global Markets Ltd. in London, but according to Bafin it remains responsible for the appropriate design of the trading system.
Write to Matthias Goldschmidt at matthias.goldschmidt@wsj.com
(END) Dow Jones Newswires
June 20, 2024 06:47 ET (10:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks